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Abstract: The acute tryptophan or tyrosine plus phenylalanine depletion and loading tests are powerful tools for studying the roles of 
serotonin, dopamine and noradrenaline in normal subjects and those with behavioural disorders. The current amino acid formulations 
for these tests, however, are associated with undesirable decreases in ratios of tryptophan or tyrosine plus phenylalanine to competing 
amino acids resulting in loss of specificity. This could confound biochemical and behavioural findings. Compositions of current formu-
lations are reviewed, the biochemical principles underpinning the tests are revisited and examples of unintended changes in the above 
ratios and their impact on monoamine function and behaviour will be demonstrated from data in the literature. The presence of excessive 
amounts of the 3 branched-chain amino acids Leu, Ile and Val is responsible for these unintended decreases and the consequent loss of 
specificity. Strategies for enhancing the specificity of the different formulations are proposed.
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Introduction
Cerebral  monoamines  control  many  physiological 
functions, not only in the periphery, but also in the 
central nervous system. Many behavioural processes 
in the brain are associated with these monoamines, 
particularly  5-hydroxytryptamine  (5-HT  or  sero-
tonin) and the catecholamines dopamine (DA) and 
noradrenaline (NA). These processes include affect, 
aggression, anxiety, appetite, arousal, cognition, drive, 
emotions, impulsivity, mood, movement, reward and 
self-control.  The  acute  tryptophan  (Trp)  depletion 
(ATD) and loading (ATL) tests1 are powerful research 
and diagnostic tools for studying the role of serotonin 
in some of the above behaviours in healthy volunteers 
and in those with psychiatric and other behavioural 
disorders. Thus, hundreds of such studies have admin-
istered these tests to examine behaviour in healthy 
volunteers1–4  and  many  disease  conditions,  includ-
ing aggressive behaviour,5 alcoholism,6 Alzheimer’s 
disease,7 anorexia nervosa,8 anxiety disorders,9 autis-
tic  disorder,10  bipolar  affective  disorder,11  bulimia 
nervosa,12  depression,13  insomnia,14  irritable  bowel 
syndrome,15  obsessive-compulsive  disorder,16  panic 
disorder,17 premenstrual syndrome,18 schizophrenia19 
and seasonal affective disorders.20
The acute tyrosine (Tyr) and phenylalanine (Phe) 
depletion (ATPD) test21 is similarly used to assess 
the role of the catecholamines dopamine (DA) and 
noradrenaline (NA) in normal subjects and those with 
psychiatric and other behavioural disorders. Because 
of the preferential role of serotonin in many of the 
conditions described above and as the ATPD test21 
was developed 11 years after the ATD test,1 fewer 
studies of the ATPD test have been performed, e.g. 
in healthy volunteers,22,23 cigarette smokers,24 depres-
sion25 and manic illness.26 As far as we could ascer-
tain, no attempts have been made to study the effects 
of acute Tyr and Phe loading (ATPL) by giving amino 
acid mixtures rich in Phe and Tyr. Previous studies 
on Tyr loading were performed mainly in animals, 
examined aspects such as acute stress, the acute respi-
ratory syndrome, endurance, muscle strength and cat-
echolamine excretion, and involved administration of 
a single dose of Tyr, usually alone, but sometimes in 
combination with another amino acid (see, e.g. ref27).
More recently, some investigators28–31 have attempted 
to  investigate  behavioural  measures  under  condi-
tions leading to simultaneous depletion of   serotonin, 
dopamine and noradrenaline by   performing combined 
ATD  and ATPD  depletion  tests  by  giving  an  amino 
acid mixture lacking in all three relevant amino acids, 
namely Trp, Phe and Tyr.
In this review, the nature and biochemical basis 
of  the  above  tests  will  be  discussed,  drawing  on 
  important  biochemical  mechanisms  derived  from 
animal  studies.  The  poor  specificity  in  humans  of 
the current amino acid test and control formulations 
will be demonstrated, its cause will be identified and 
  strategies for enhancing it will be proposed. In   seeking 
to illustrate the above aspects, this review will not be 
exhaustive and will be limited as far as possible to 
human studies, as species differences in amino acid 
metabolism render direct comparison difficult.
nature of the tests and their current 
amino acid formulations
Both  the  ATD  and  ATPD  tests  involve  administra-
tion to the subjects under study of a mixture of up to 
15 amino acids (AA) (both essential and non-essential) 
which lack tryptophan (Trp) (for the ATD test) or lack 
phenylalanine (Phe) and tyrosine (Tyr) (for the ATPD 
test). Both Phe and Tyr, rather than Tyr alone, must 
be omitted from the formulation, because Phe can be 
converted to Tyr by Phe or Tyr hydroxylase.32,33 By the 
same token, when loading, as opposed to depletion, is 
required, the amino acid mixture will then contain an 
excess of Trp (for acute Trp loading or ATL) or an excess 
of Phe and Tyr (for acute Phe plus Tyr loading or ATPL) 
and moderate amounts of the corresponding amino acids 
(Phe and Tyr for the ATL and Trp for the ATPL tests). 
Additionally, in either the depletion or loading studies, 
a “balanced” amino acid mixture is administered as a 
control   treatment. This control   formulation will contain 
the same AA used in the depletion or loading tests, but 
with moderate amounts of Trp, Phe and Tyr.
Table 1 gives the amino acid (AA) composition of 
the ATD, ATL and control balanced formulation origi-
nally published by Young et al1 in amounts per a 100 g 
dose. Because women weigh on average 16.7% less 
than men, the original 103 g AA   mixture used by this 
Canadian research group was subsequently lowered 
to 85.5 g for studies in women.2 Other investigators 
have introduced minor variations to the above origi-
nal formulation,1 mainly to increase the Trp content 
in the control formulation to varying extents. These 
variations will be discussed below.Biochemical aspects and poor specificity of current amino acid formulations
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Table 1. Amino acid composition of the original acute tryptophan depletion, loading and control formulations of Young 
et al.1
Amino acid Formulation Amount (g) Amino acid Formulation Amount (g)
Trp Depletion 0.00 Arg All 4.90
Loading 10.30 cys* 2.70
control 2.30 gly 3.20
Leu All 13.50 his 3.20
Val 8.90 Lys 8.90
Ile 8.00 Met* 3.00
Tyr 6.90 Pro 12.20
Phe 5.70 ser 6.90
Ala 5.50 Threo 6.50
Amounts of amino acids are in g per a 100 g formulation. The * denotes that, these two amino acids are given in capsules due to their offensive odours 
and tastes.
Table  2.  Amino  acid  composition  of  the  control  and 
test    formulations  for  acute  tyrosine  plus  phenylalanine 
  depletion (ATPD) by sheehan et al.21
Amino acid Control  
formulation
ATPD 
formulation
Trp 2.17 2.78
Leu 19.56 25.00
Val 15.22 19.44
Ile 13.05 16.67
Phe 10.87 0.00
Tyr 10.87 0.00
Lys 15.21 19.44
Met 4.35 5.56
Threo 8.70 11.11
Total 100.00 100.00
In the original formulation,21 the total amounts of amino acids were 57.5 g 
(control) and 45 g (ATPD). Amounts have been adjusted here to a total of 
100 g for comparative purposes with other formulations.
For the ATPD test, two AA formulations have been 
used. In the first, designed by the group in Oxford 
(Sheehan et al),21 only 7 amino acids were used, which 
were supplemented with Phe and Tyr in the control 
formulation. The AA composition of the ATPD test 
and  its  control  as  reported21  is  shown  in  Table  2. 
Because the original amounts of AA added up to only 
45 g in the depletion- and to 57.5 g in the control, 
formulation, the AA amounts shown in Table 2 here 
have been adjusted to a total dose of 100 g.
In the other formulation for the ATPD test, reported 
by the Canadian group (Ellenbogen et al),2 authors 
of  the  original ATD  formulation,1  the  composition 
resembled more closely that used in the ATD and ATL 
tests,1 namely containing the same 15 AA originally 
used. Thus, the compositions of the ATPD and its con-
trol formulation used by Leyton et al28 based on those 
adapted for women by Ellenbogen et al2 is shown in 
Table 3 below. Because the total amount of AA in the 
control formulation was only 85.5 g, the contents in 
Table 3 have been adjusted to a 100 g total for both 
the control and ATPD formulations, though the lat-
ter is short of the contents of Phe and Tyr. As was 
the case with ATD and ATL, other investigators have 
used the above two formulations for ATPD21,28 with 
minimal variations.
From the data in Tables 1–3, it is clear that there 
are 6 amino acids which must all be present in the 
control formulation, but that some of which must be 
absent in the depletion, or present in excess in the 
loading, formulation (namely Trp, Phe and Tyr). The 
remaining 3 amino acids always present in all formu-
lations are the branched-chain amino acids (BCAA) 
valine  (Val),  leucine  (Leu)  and  isoleucine  (Ile). 
Their  concentrations,  sums  and  proportions  in  the 
various formulations are shown in Table 4 and their 
significance will be discussed below. As shown in 
Table 4, the content of BCAA as a proportion of the 
total amino acid content of the different formulations 
ranges between 29% and 33% in the formulations of 
the Canadian group,1,28 as opposed to the much larger 
content (48%–61%) in those of the Oxford group.21
Physiological and Behavioural  
Effects of the Formulations
The effects of the above formulations can be   classified 
into those: 1) caused by the amino acid mixtures them-
selves; 2) resulting from modulation of levels of the 
three monoamines 5-HT, DA and NA. The amino acid 
formulations  are  generally  unpalatable  and  induce 
changes varying between slight nausea and drowsiness Badawy et al
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Table 3. Amino acid composition of the control and test 
formulations for acute tyrosine plus phenylalanine deple-
tion (ATPD) by ellenbogen et al2 as detailed by Leyton 
et al.28
Amino acid Control  
formulation
ATPD 
formulation
Trp 2.17 2.22
Leu 12.93 13.22
Val 8.47 8.65
Ile 7.66 7.84
Phe 5.49 0.00
Tyr 6.64 0.00
Lys 10.53 10.76
Met 2.86 2.92
Threo 6.18 6.32
Ala 5.26 5.38
Arg 4.69 4.79
cys 2.63 2.69
gly 3.09 3.16
his 3.09 3.16
Pro 11.67 11.93
ser 6.64 6.78
Total 100.00 89.82
Amounts of amino acids are in g in the total contents indicated.
Table 4. contents of branched-chain amino acids (BcAA) in the original control and test formulations for acute tryptophan 
and tyrosine plus phenylalanine depletion. 
Parameter Young et al1 Leyton et al28 Sheehan et al21
Test ATD Control ATPD Control ATPD Control
[Leu] 13.50 13.50 13.22 12.93 25.00 19.56
[Val] 8.90 8.90 8.65 8.47 19.44 15.22
[Ile] 8.00 8.00 7.84 7.66 16.67 13.05
[BcAA] 30.40 30.40 29.71 29.06 61.11 47.83
[Total] 100.00 102.30 89.82 100.00 100.00 100.00
BcAA (%) 30.40 29.72 33.08 29.06 61.11 47.83
Amounts of the 3 branched-chain amino acids and their sum (BcAA) are in g per the total content of amino acids in the formulations, from which the 
proportion of BcAA (as a %) is calculated.
to severe nausea and emesis,1,21,34 resulting in drop-out 
of study subjects. The latter authors34 addressed the 
question of side effects during ATD and ATL at the 
50 g and 100 g dose levels in detail, using a bodily 
symptom scale that assesses a variety of symptoms 
ranging from sweating, fast heart, shaking, dizziness, 
irritability, nausea, anxiety, depression, tension, head-
ache and loss of appetite, to loss of concentration, tired-
ness and stomach ache. They found that, during ATD, 
there was no dose difference in the increases in the 
above side effects, which were highest in the last three 
symptoms above. During ATL, a clear dose difference 
was observed, with subjects   receiving the 100 g dose 
showing significantly greater side effects. As a result 
of  these  side  effects,  these  authors34  reported  attri-
tion, which was confined to female subjects receiv-
ing the 100 g ATD or ATL dose, and, to avoid side 
effects and attrition and their effects on sample size 
and interpretation of behavioural data, these authors 
recommended the use of a 50 g dose in both ATD and 
ATL studies. Side effects after ATPD have not been 
studied in detail.
The effects of the above formulations resulting from 
modulation of central monoamines involve changes 
in mood, behaviour and cognition. The effects of ATD 
have recently been reviewed.35 Briefly, in healthy sub-
jects, ATD lowers mood in females, in those with a 
baseline depression score at the upper end of normal, 
or in subjects vulnerable to disturbances in central 
serotonin. By contrast, transient lowering of mood is 
a more consistent observation after ATD in patients 
with  remitted  depression.  ATD  also  affects  other 
behaviours, such as social behaviour, aggression and 
impulsivity, all of which may be closely connected 
to the serotonin system. ATD also affects a variety of 
cognitive processes in both healthy subjects and those 
with a serotonergic vulnerability. In particular, ATD 
impairs  declarative  episodic  memory  processes  of 
delayed recall and memory consolidation, learning on 
visual discrimination and memory retrieval, episodic 
memory, stimulus reward learning and cognitive flex-
ibility (for references, see35). Much less work has been 
done on the effects of ATPD on mood, behaviour and 
cognition, most of which in healthy subjects. Thus, a 
study36 of 12 healthy subjects suggested that ATPD 
does  not  alter  mood,  measures  of  memory,  atten-
tion or behavioural inhibition. However, other stud-
ies in healthy subjects showed that ATPD increases Biochemical aspects and poor specificity of current amino acid formulations
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  vulnerability to lowered mood following exposure to 
aversive psychological events37 and impairs affective 
processing38 and spacial working memory.29 In manic 
patients, Tyr depletion by administration of BCAA 
ameliorates manic symptoms.39
Principles of the Tests
These tests are based on a number of biochemical, 
metabolic and physiological principles, which are set 
out below first for the role of Trp in serotonin syn-
thesis,  then  that  of  Phe  and  Tyr  in  catecholamine 
synthesis.
Role of tryptophan  
in serotonin synthesis
As the rate-limiting enzyme of serotonin synthesis, Trp 
hydroxylase, is unsaturated with its Trp substrate,40 
brain [Trp] is the most important single metabolic 
determinant of the rate of serotonin synthesis41 under 
acute short-term conditions. Although other important 
determinants include the rates of synthesis and deg-
radation of Trp hydroxylase, its state of phosphoryla-
tion, the rate of firing of serotonergic neurons, and the 
influence of other neurotransmitters on this firing, it is 
unlikely that, under acute conditions, these determi-
nants play a primary role in the rapid changes in sero-
tonin synthesis observed during the ATD test. This is 
because of Trp hydroxylase having a relatively long 
half-life of 2–3 days, a slow axonal transport (∼7 mm 
per day)42 and its phosphorylation under optimal con-
ditions  enhances  its  activity  by  only  10%–30%.43 
Moreover,  none  of  these  factors  can  influence  the 
rate of Trp hydroxylation in vivo optimally without 
adequate levels of the Trp substrate. As Trp cannot 
be synthesized by the body, peripheral factors influ-
encing its entry into the brain play important roles in 
the control of central serotonin synthesis under acute 
conditions.  These  factors  include,  primarily,  liver 
Trp pyrrolase (Trp 2,3-dioxygenase),44–46 and at the 
secondary, but more immediate, level, Trp binding 
to albumin47 and competition for entry into the brain 
from several amino acids, notably the branched-chain 
amino acids (BCAA) Val, Leu, and Ile, and the aro-
matic Phe and Tyr, collectively known as the com-
peting amino acids (CAA).48 As regards Trp binding, 
although kinetic studies based on plasma perfusion49 
and  intravenous  administration50,51  techniques  and 
correlational   studies of plasma free [Trp] and the free 
[Trp]/[CAA] ratios with changes in central 5-HT syn-
thesis and mood13,52 all favour free Trp, there is also 
evidence for rapid equilibration between the free and 
albumin-bound fractions.47,53 It is therefore important 
to estimate both the free and total [Trp] fractions3 and 
their ratios to [CAA] as the most accurate predictors 
of changes in brain [Trp] and hence in 5-HT synthe-
sis. In the ATD test, the free and total [Trp]/[CAA] 
ratios are dramatically decreased by at least 90% as 
a result of: a) the presence of the 5 Trp competitors; 
and b) the severe Trp depletion induced by: 1) omis-
sion of Trp; 2) stimulation of protein synthesis;54,55 
and 3) any prior nutritional intervention in the form 
of low-protein (i.e. low Trp) food intake.56,57
Role of tyrosine and phenylalanine  
in catecholamine synthesis
The role of Phe and Tyr in catecholamine synthesis is 
based on broadly similar principles. Thus, the rate-lim-
iting enzyme of catecholamine synthesis, Tyr hydroxy-
lase, is also partially saturated with its Tyr substrate,40 
though less so (∼75% versus 50% for Trp hydroxy-
lase). Tyr hydroxylase activity and hence the rate of 
catecholamine synthesis can therefore be influenced 
by changes in Tyr availability to the brain.58–63 This 
availability is also best expressed by the corresponding 
ratio, namely that of [Phe + Tyr]/[BCAA + Trp].
The  potential  effects  of  Tyr  loading  on  cat-
echolamine  synthesis  have  received  lesser  atten-
tion, despite existing evidence. Thus, excess Tyr in 
the  brain  is  not  always  reflected  in  enhanced  cat-
echolamine synthesis or turnover.40,57,64 This may be 
due to either feedback40,64 or substrate59 inhibition of 
Tyr hydroxylase activity. The latter authors59 showed 
that Tyr hydroxylase is activated in vivo (as assessed 
by Dopa formation after NSD-1015) by small or mod-
erate elevations in brain [Tyr] (not exceeding 50%), 
but inhibited by larger concentrations, with almost 
complete inhibition when brain [Tyr] is increased by 
100% or more. This may explain why, in one of the 
above studies,57 CSF [Tyr] was elevated in some par-
ticipants, in some cases by ∼3-fold, whereas no eleva-
tion in the DA metabolite homovanillic acid (HVA) 
was observed. The elevation of CSF [Tyr] in this ATD 
study57 is, however, surprising and difficult to explain, 
as the authors did not provide information on Tyr 
availability to the brain. From the above account, it 
is clear that investigators should always pay attention Badawy et al
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to the role of Tyr, bearing in mind that small or large 
decreases  in  brain  [Tyr]  can  inhibit  catecholamine 
synthesis, whereas stimulation of this synthesis after 
Tyr elevation (e.g. after loading) will depend on the 
extent of this elevation.
Poor Specificity of Current  
Amino Acid Formulations
Definitions of specificity
Specificity  of  the  ATD  or  ATL  test  formulation 
implies  that  only  the  rate  of  serotonin  synthesis 
will be decreased or increased respectively, with 
no change to the rate of dopamine or noradrenaline 
synthesis. Therefore one would expect that, whereas 
the [Free Trp]/[CAA] and [Total Trp]/[CAA] ratios 
will be either decreased (after ATD) or increased 
(after  ATL),  that  of  [Phe  +  Tyr]/[BCAA  +  Trp] 
should  remain  unaltered  from  the  baseline  value 
before intake of the AA formulations. By the same 
token, specificity of the ATPD or ATPL tests implies 
that, whereas the [Phe + Tyr]/[BCAA + Trp] ratio is 
either decreased (after ATPD) or increased (after 
ATPL), those of [Free Trp]/[CAA] and [Total Trp]/
[CAA] should remain unaltered from baseline. As 
regards  the  control  formulation(s)  for  the  ATD, 
ATL, ATPD or ATPL tests, all three ratios should 
remain unaltered from baseline. In practice, existing 
AA formulations do not show this specificity and 
the following sections will demonstrate this defect 
and provide an explanation for it and a means of its 
rectification.
Previous demonstration  
of lack of specificity
Reilly et al3 noted that many investigators using the 
ATD or its control formulation did not determine the 
free or total [Trp]/[CAA] ratio and only a few mea-
sured  peripheral  levels  of Tyr  or  its  ratio  to  other 
competing amino acids. While it must be assumed 
that  the  [Trp]/[CAA]  ratio  is  decreased  after ATD 
and increased after ATL, a decrease in this ratio has 
also been observed with a 100 g “balanced”   control 
  formulation for ATD containing the usual 2.3 g of 
Trp.65 This ratio was also decreased in the control for-
mulation if the Trp content was increased to 3.0 g,66 
but further increases to 4.1 g67 or 4.6 g68 of Trp caused 
elevations of this ratio. From data from our previ-
ous detailed pharmacokinetic and behavioural study 
  comparing a 50 g with the traditional 100 g dose of 
the amino acid formulations for the ATD and ATL 
tests,34 we reported69 that intake of 50 g of the control 
formulation containing 1.15 g of Trp decreased the 
[Free Trp]/[CAA] ratio maximally by 61%.
We also found that the [Phe + Tyr]/[BCAA + Trp] 
ratio was decreased in the ATD, ATL and also in the 
control formulation by about 50%. Broadly similar 
decreases (40%–60%) in this latter ratio have been 
reported previously36,70,71 in control formulations used 
in the ATPD test, which are essentially similar to the 
control formulation for the ATD or ATL test. Further-
more, in the ATPD test, both the control and the Phe 
plus Tyr-deficient formulations are associated with 
decreases in the [Trp]/[CAA] ratio, of 30%–62% with 
the control formulation, and of 34%–96% with the 
depleting formulation.21,36,37,71–73
Reasons for lack of specificity
The main, if not only, reason for the above undesir-
able decreases in the [Phe + Tyr]/[BCAA + Trp] and 
[Trp]/[CAA] ratios in the control or the correspond-
ing relevant depletion (or loading) formulations is the 
relatively larger contents of the three BCAA (i.e. Leu, 
Val and Ile), compared with those of Phe, Tyr and/or 
Trp, in the original Trp1 or Tyr + Phe21 formulation. 
The differences in contents of these 6 competitors is 
clearly reflected in the disproportionate increases in 
their plasma concentrations across the entire 7h time-
course of administration of the 50 g control formula-
tion in our previous study34 illustrated here in Fig. 1, 
where the order of the absolute increases was as fol-
lows: Val . Leu . Ile . Trp . Phe . Tyr, whereas 
that of the increases relative to baseline was: Ile . 
Leu . Trp . Val . Tyr . Phe. In either case, Phe 
and Tyr were at the greatest disadvantage, followed by 
Trp. The decrease in the [Phe + Tyr]/[BCAA + Trp] 
ratio was even greater after ATL, because of the extra 
large increase in [Trp] that is combined with the high 
[BCAA].69
Basis of the amino acid composition 
of the original formulations
In  the  original  ATD,  ATL  and  their  control 
formulations,1 the choice of an amino acid mixture 
with a composition based on human milk was a fortu-
nate one in that it ensured a high level of the 3 BCAA 
Val, Leu and Ile to achieve a strong competition with Biochemical aspects and poor specificity of current amino acid formulations
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Figure  1.  Time-course  of  changes  in  plasma  competing  amino  acid 
conentrations following oral intake of a 50 g dose of the control formula-
tion for the acute tryptophan depletion and loading tests. 
Note: Values are means ± seM for each group of 12 subjects. Adapted 
from the data in Table 3 in Dougherty et al (2008).34
Trp for entry into the brain. The presence of high con-
centrations of these 3 BCAA in human milk is of par-
ticular importance in human physiology, as BCAA, 
particularly Leu, are vital and essential for protein 
synthesis and hence the growth of the infant.74 How-
ever, the use of a composition based on human milk 
as a control formulation is not necessarily the best 
choice for a human adult undergoing ATD or ATL 
studies, as its large content of BCAA is the cause 
of the decreases in the [Trp]/[CAA] and the [Phe + 
Tyr]/[BCAA + Trp] ratios in the control or the rel-
evant depletion formulation. By the same token, in 
the original formulation for ATPD,21 the content of 
the 3BCAA was even greater (48%–61% of the total 
AA content) than in the ATD-related formulations1 
(29%–33% of the total AA content), as illustrated in 
detail in Table 4 above.
Implications of the Lack of Specificity 
in Interpretation of Biochemical and 
Behavioural Data
Biochemical considerations
The above decreases in the [Trp]/[CAA] and [Phe + 
Tyr]/[BCAA + Trp] ratios therefore suggest that 5-HT, 
DA and/or possibly NA synthesis could be inhibited 
by  the  control  formulation  and  the  corresponding 
ones  for  ATD,  ATPD  and  their  loading  counter-
parts,  an  effect  that  could  confound  interpretation 
of behavioural changes (or lack of them). Whereas 
the role of brain Trp in serotonin synthesis is now 
well-established (see above), that of brain Tyr in cat-
echolamine synthesis has received less attention in 
human studies, despite existing evidence. For exam-
ple, the relationship between Tyr depletion and DA 
synthesis in various brain structures has been stud-
ied in detail in rats. Carlsson and Lindqvist40 found 
that the rate of Tyr hydroxylation in vivo (determined 
by accumulation of Dopa after decarboxylase inhi-
bition  by  compound  NSD-1015)  was  significantly 
decreased in several brain areas when [Tyr] in these 
areas was decreased by 26% or more, with a 65% 
decrease in [Tyr] leading to a 34%–41% decrease in 
[Dopa]. These findings were confirmed by McTavish 
et al,75 who found that a 50%–60% decrease in [Tyr] 
was associated with a 20%–44% drop in [Dopa].
The question then arises as to whether decreases 
in the above ratios of the order of 50%–60% lead-
ing  to  significant  decreases  in  synthesis  of  5-HT, 
DA  and/or  NA  can  alter  monoamine  function  and 
thus  influence  behaviour. As  regards  DA  function, 
the above decrease in DA synthesis75 was accompa-
nied by an even-stronger decrease in amphetamine-
induced  DA  release.  In  a  dose-finding  study71  in 
healthy adults, plasma levels of prolactin, a surro-
gate marker of DA function that is elevated when DA 
levels  are  decreased,  were  moderately  elevated  by 
a 10 g dose of BCAA, which decreased the [Tyr + 
Phe]/[BCAA] ratio by 70%. The [Trp]/[CAA] ratio 
was also decreased by this small dose of BCAA by 
58% (the resulting decrease in 5-HT synthesis would 
be expected to cause a decrease in prolactin) and had 
this ratio decrease been avoided, the elevation of pro-
lactin could have been greater. Also, it was found76 
that serotonin depletion induced by a Trp-deficient 
diet enhances amphetamine-induced DA release and 
causes a greater increase in motor activity than in con-
trols. In a positron-emission tomographic study,77 it 
was estimated that a modest decrease in brain [DA] of 
10%–20% after ATPD in normal subjects can explain 
the 6% increase in [11C] raclopride binding, which 
results from DA receptors no longer being occupied 
by DA, and suggested that the decrease in the [Phe + 
Tyr]/[BCAA] ratio observed with the control formu-
lation could have also increased this binding, relative 
to a control which did not decrease this ratio. It thus 
appears that DA function can be undermined by the 
changes in brain DA and the [Phe + Tyr]/[BCAA + 
Trp] ratio observed with the control formulations.Badawy et al
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Behavioural considerations
In general, behaviour does not seem to be influenced in 
normal volunteers of either gender by the ATPD or its 
control formulation.36 Behaviour is also not influenced 
by the control formulation for ATD or ATL in normal 
males or females, nor in males undergoing ATD: only 
ATD in normal females may influence behaviour.2,35 
The  situation  in  patient  populations  is,  however, 
different, not only regarding ATD, which can pre-
cipitate a depressive episode in recovered depressed 
subjects,13  but  also  the  control  formulation  itself. 
Thus, e.g. in depressed patients, the free and/or total 
[Trp]/[CAA] ratio is already known to be decreased by 
16%–36% relative to controls.78–84 Total [Trp] is also 
known to be decreased in depressed patients by 20%–
29%.78,79,82,83,85 In 4 of the studies listed above which 
reported both parameters simultaneously,78,79,82,83 the 
decreases in the total [Trp] and total [Trp]/[CAA] ratio 
were  generally  comparable  (respectively  26%  and 
23%; 26% and 23%; 20% and 18%; 29% and 32%). 
Thus, in depressed individuals, a further decrease of 
50%–60% induced by the control formulation might 
lead to an even greater depletion of brain serotonin. 
Even  if  monoamine-dependent  behaviour  does  not 
appear to be influenced when measured by existing 
instruments,  investigators  using  a  control  formula-
tion in the knowledge that it will decrease the Trp and 
Tyr ratios by ∼50% in control subjects could not rule 
out a greater decrease in patient populations, which 
may precipitate significant behavioural changes. In 
fact, it has been suggested86 that mood can be sig-
nificantly altered when the decline in plasma [Trp] 
is  .60%,  a  value  that  could  be  reached  easily  in 
patients receiving the control formulations in their 
present compositions.
The Need to Enhance the Specificity 
of the Control and Other Amino Acid 
Formulations
We believe that: 1) it is inappropriate to argue that 
the  use  of  a  control  formulation  which  alters  the 
above ratios so significantly is permissible as long 
as it does not affect behaviour measured by exist-
ing instruments; 2) it would be both impractical and 
confusing to use two control formulations: one for 
normal subjects (whose behaviour may or may not 
be impaired) and the other for patient groups, who, 
by virtue of having a low or borderline [Trp]/[CAA] 
ratio are likely to experience greater ratio decreases 
and consequently behavioural changes; 3) it is more 
prudent to err on the side of accuracy and establish 
a truly balanced control formulation which does not 
alter these ratios.
Previous attempts to enhance the 
specificity of the control formulation  
for tryptophan depletion
Three previous attempts have been made to over-
come the above ratio changes, but with only par-
tial success. In the first, Weltzin et al87 succeeded 
in  maintaining  the  baseline  [Trp]/[CAA]  ratio  by 
increasing the Trp content to 4.6 g/100 g of the tra-
ditional amino acid mixture. However, they did not 
measure the [Phe + Tyr]/[BCAA + Trp] ratio and it 
is almost certain that, with this level of Trp load-
ing (which is 45% of that of the ATL dose), or even 
without it, this latter ratio will have been decreased. 
Booij et al88 used a low dose ATD (25% of the nor-
mal one) as a control [based on a previous design 
by Krahn et al89]. However, although this low-dose 
mixture did not alter the [Tyr]/[CAA] ratio, it still 
decreased the [Trp]/[CAA] ratio by 42%, against a 
92% decrease by the full dose. However, interpreta-
tion of some, or all, of these biochemical changes is 
difficult because the subjects consumed a lunch dur-
ing the test procedure. Still, while the use of a low-
dose mixture may be useful in studies examining the 
effects of sub-optimal depletion of Trp and 5-HT, it 
cannot be considered an appropriate control for the 
ATD test dose. As regards the ATPD and its control 
formulation, no previous attempts have been made to 
address the issue of their specificity.
Biological and behavioural reasons  
for improving the specificity  
of the control formulations
The  need  for  a  truly  balanced  control  or  test 
  formulation  has  already  been  emphasized.3  Most 
investigators using the ATD or ATL (or the ATPD 
or  ATPL)  tests  would  agree  that  a  “balanced” Biochemical aspects and poor specificity of current amino acid formulations
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  formulation should ensure that the control treatment 
maintains baseline values without altering the bio-
chemical or behavioural parameters being studied, 
which  would  further  enhance  accurate  interpreta-
tion of results. As BCAA play a pivotal role in the 
ATD test, the use of a balanced control formulation, 
rather  than  an  amino-acid-free  “neutral”  placebo, 
is  even-more  important,  particularly  in  relation  to 
behavioural studies, because, apart from inducing a 
central 5-HT deficiency through Trp depletion and 
a central catecholamine deficiency through Phe and 
Tyr depletion, the BCAA have the potential to exert 
other  equally  important  metabolic  changes  which 
could also further impact behaviour (for commen-
tary, see Ref74). Thus, in the human brain, BCAA 
are  transaminated  by  branched-chain  amino  acid 
aminotransferase  (BCAT)  to  branched-chain  keto 
acids,  converting  in  the  process  2-oxoglutarate  to 
glutamate.74,90 BCAA are thus nitrogen donors for the 
synthesis of the excitatory amino acid glutamate and 
the inhibitory neurotransmitter γ-aminobutyric acid 
(GABA), with Leu playing a particularly prominent 
role90–92 and it is noteworthy that the brain cytosolic 
isoenzyme of BCAT is located in GABAergic and 
glutamatergic neurons.93 Since in humans, the brain 
normally accounts for 10%–20% of their total body 
metabolism,94 a significant increase could be expected 
after loading with BCAA, as during the depletion 
or loading tests, resulting in enhanced synthesis of 
glutamate  and  GABA.  Changes  in  glutamatergic 
and/or GABAergic neurotransmission are therefore 
expected under these conditions, which could impact 
on 5-HT and dopamine functions, with the potential 
to modulate behaviours associated with these cere-
bral monoamines.
Strategies for Enhancing the 
Specificity of the Control and Test 
Formulations for Acute Tryptophan 
and Tyrosine Plus Phenylalanine 
Depletion and Loading
In the light of this and the preceding discussion, 
and based on theoretical graphs designed to main-
tain normal [Trp]/[CAA] and [Phe + Tyr]/[BCAA + 
Trp] ratios under the depletion, loading, or balanced 
(control) condition, if the contents of the [BCAA] 
or of [Phe + Tyr] were to be altered independently, 
we   proposed69 two strategies for normalizing these 
ratios: (1) decreasing the contents of the three BCAA 
by ∼30%; or (2) increasing those of Phe and Tyr by 
∼50%. Of these, the first is the preferred strategy, 
because  it  avoids  the  metabolic  consequences  of 
Phe and Tyr loading associated with the latter strat-
egy, because, if adopted, it could contribute to a fur-
ther lowering of both the free and total [Trp]/[CAA] 
ratios in the control formulation. A third strategy, 
applicable  only  to  the  control  formulation,  is  to 
increase the Trp content, as performed previously.87 
However, while this may improve the [Trp]/[CAA] 
ratio, it can only further decrease the [Phe + Tyr]/
[BCAA + Trp] ratio and thus lead to a greater deple-
tion of brain catecholamines. As BCAA appear to be 
the components of amino acid mixtures responsible 
for the undesirable decreases in the above ratios, 
we believe that modulating their content in the vari-
ous formulations is the most appropriate strategy 
for  enhancing  the  specificity  of  these  important 
research and diagnostic tests.
Conclusions and Comments
We hope that this review has addressed the impor-
tant biochemical principles underpinning the acute 
Trp and Tyr plus Phe depletion and loading tests, 
illustrated clearly the poor specificity of the various 
test and control amino acid formulations and made 
constructive  proposals for  improving their  speci-
ficity. In the accompanying paper, we successfully 
demonstrate the normalisation of the free and total 
[Trp]/[CAA] and [Phe + Tyr]/[BCAA + Trp] ratios 
in a new balanced control formulation for all the 
above tests by decreasing the content of BCAA, and 
propose adjustments of the contents of the active 
formulations to ensure their specificities.
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